Top 9 Urology startups in USA
Apr 14, 2026
|
Like
16
1
Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
2
Funding: $237.5M
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
3
Funding: $125.4M
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
4
Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
5
Funding: $29.1M
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
7
Funding: $9.1M
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
8
Funding: $3.8M
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
9
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
★
See also:
